TrialPath
Recruiting

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

NCT07224464 · New Phase Ltd.
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Open Label Feasibility Dose Escalation Study to Evaluate the Safety of Sarah Nanotechnology System, With Alternating Magnetic Field (AMF) Application in Patients With Advanced Metastatic Solid Tumors.
About this study
This is a sequential, open-label, dose-escalation, non-randomized, prospective early feasibility clinical investigation designed to evaluate the safety of the Sarah Nanotechnology System, comprising intravenously administered Sarah Nanoparticles (SaNPs) in combination with a low-frequency Alternating Magnetic Field (AMF) generated by the Electromagnetic Induction System (EIS). The purpose of the study is to assess the safety profile of the SaNP and AMF combination and to identify the recommended dose and irradiation parameters for a subsequent feasibility study. The study will also provide initial information regarding device performance and efficacy. Scientific and Technical Background: The Sarah Nanotechnology System utilizes controlled magnetic hyperthermia to thermally damage malignant cells while sparing surrounding healthy tissue. Following a single intravenous administration, SaNPs, nanoparticles with iron oxide core, circulate systemically and preferentially accumulate within tumor tissue through the Enhanced Permeability and Retention (EPR) effect, then participant's upper torso is exposed to an AMF (≈ 290 ± 10% kHz) by the EIS (Electromagnetic Induced System). The obtained effect is heating at tumor site. Because AMF exposure can also induce eddy currents on the skin surface a patient cooling blanket system continuously helps regulating body surface temperature. Vital signs and skin temperature are monitored in real time throughout irradiation. Dose-Escalation Design: The study follows a standard 3 + 3 sequential escalation design, once the recommended dose is identified, an expansion cohort will repeat it. SaNP dose: 100% SaNP dose, calculated according to NOAEL. AMF parameters: 290 ± 10% kHz; total irradiation time up to 15 minutes in the first treatment cohort, increasing to 16-20 minutes at the next treatment cohort depending on safety review. Dose-limiting toxicity (DLT) criteria and escalation rules follow standard early-phase device study methodology. Treatment Procedure: On the treatment day, participants undergo laboratory tests and ECG assessment before SaNP infusion. Approximately four hours post-infusion, participants are positioned within the EIS coil for AMF irradiation while covered by a cooling blanket, and analgesic administration per physician discretion. Skin surface and oral temperatures, vital signs, and participant comfort are continuously monitored. After irradiation, repeat laboratory and ECG evaluations are performed prior to discharge. Follow-up assessments occur at 7 ± 2 days and 30 ± 5 days post-treatment and then every 3-6 months up to 5 years for long-term safety surveillance. Adverse events (AEs) and serious adverse events (SAEs) will be documented and evaluated for severity and relatedness to device or procedure. Real-time safety oversight is performed by the investigator and sponsor medical monitor; the DSMB periodically reviews cumulative safety data and recommends escalation, expansion, or study termination.
Eligibility criteria
Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have progressed on or after standard therapy and are ineligible for surgical resection or local therapies. 3. Must have measurable disease according to RECIST 1.1. 4. Locally advanced or metastatic disease which is not amenable to curative therapy and has progressed on or is intolerant to standard available therapy as deemed by the investigator. 5. There must be resolution of all systemic treatment-related adverse events. At least 14 days must have elapsed since the last systemic or radiotherapy treatment before screening visit. 6. Documented progressive disease confirmed by either CT (chest and abdomen), MRI or PET/CT scan since patient's last cancer therapy. 7. No prior history of brain metastasis confirmed by CT or MRI within 30 days prior to treatment. 8. Treatment planning CT scan performed within 14 days prior to study treatment. 9. Age ≥18 years. 10. Rib cage circumference ≤ 90 cm. 11. Eastern Cooperative Oncology Group (ECOG) performance status ≤2. 12. Patients should have sufficient organ and bone marrow function on screening day and on procedure day as defined below: Leukocytes ≥3,000/mcL Absolute neutrophil count ≥1,500/mcL Platelets ≥100,000/mcL Total bilirubin ≤ 2.5 x limit of normal (ULN) AST(SGOT)/ALT(SGPT) ≤5 x institutional ULN Creatinine Glomerular filtration rate (GFR) ≥50 ml/min/1.73 m2 for patients with creatinine levels above institutional normal. 13. Ability to provide written informed consent document. 14. Confirmation that patient has no electronic or electronically conductive implants or metals: * Via a review of the CT scan * Metal questionnaire filled in by patients Exclusion Criteria: 1. Received chemotherapy, radiotherapy or hormonal therapy within 14 days (before screening). 2. Received immunotherapy/biological therapy or any other investigational agent in the last 21 days (before screening). 3. Not yet recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> Grade 1). 4. Presence of brain metastases or prior history of brain metastases (if no prior history, confirmed by CT or MRI within 30 days prior to treatment). 5. Known history of allergic reactions attributed to compounds of similar chemical or biological composition (For example: PEG 20,000 Dalton). 6. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, ischemia, or psychiatric illness) that in the opinion of the investigator would either limit compliance with study requirements or put participant at risk. 7. Pregnant and/or breastfeeding. 8. Unwilling to be abstinent or on contraception for up to 30 days after the last study treatment. 9. Presence of electronic or electronically conductive implants or metals in body (verified by screening CT and metal questionnaire). 10. Rib cage circumference over 90 cm. 11. Unable to provide written informed consent. 12. Unable to lay down with hands extended over head.
Study design
Enrollment target: 12 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-12-16
Estimated completion: 2030-12
Last updated: 2026-05-15
Interventions
Device: The Sarah Nanotechnology System - intended to deliver thermal energy to malignant cells for the purpose of thermal destruction of these cells in patients with advanced metastatic solid tumors.
Primary outcomes
  • • Primary safety profile: assessing the number of device related adverse events and serious adverse events. (From treatment day and up to 1 month post treatment.)
  • • Primary safety of recommended dose: characterization of protocol dosing regimen (From treatment day and up to 1 month post treatment.)
Sponsor
New Phase Ltd. · industry
Contacts & investigators
ContactNew Phase Clinical Team · contact · clinicalstudy@newphase.co.il · +972-3-6798687
InvestigatorScott C Lester, MD · principal_investigator, Mayo Clinic, Rochester, MN
All locations (1)
Mayo ClinicRecruiting
Rochester, Minnesota, United States